Left Atrial Appendage Closure: Prevention and Management of Periprocedural and Postprocedural Complications

Ben Wilkins; Motoki Fukutomi; Ole De Backer; Lars Søndergaard

doi:10.1016/j.ccep.2019.10.003

Left Atrial Appendage Closure: Prevention and Management of Periprocedural and Postprocedural Complications

Ben Wilkins, Motoki Fukutomi, Ole De Backer, Lars Søndergaard^*

^*Corresponding author for this work

Research output: Contribution to journal › Review › Research › peer-review

15 Citations (Scopus)

Abstract

Left atrial appendage closure (LAAC) is noninferior to oral vitamin K antagonist therapy for the reduction of nonvalvular atrial fibrillation-related stroke risk. Currently, the procedure is most widely accepted in patients who cannot tolerate oral anticoagulants. This patient population is generally comorbid, making any reduction in procedural complications paramount. LAAC has important complications described in the periprocedural and postprocedural periods. The prevention and management of complications regarding vascular access, transseptal puncture, pericardial effusion, device embolization, stroke, air embolusperidevice leak, device-related thrombus and device erosion/ late pericardial effusion are discussed.

Original language	English
Journal	Cardiac Electrophysiology Clinics
Volume	12
Issue number	1
Pages (from-to)	67-75
Number of pages	9
ISSN	1877-9182
DOIs	https://doi.org/10.1016/j.ccep.2019.10.003
Publication status	Published - 2020

Keywords

Complications
Left atrial appendage closure
Management
Prevention

Access to Document

10.1016/j.ccep.2019.10.003

Cite this

@article{eb9182e9f9354674a81e35e50ae07a6c,

title = "Left Atrial Appendage Closure: Prevention and Management of Periprocedural and Postprocedural Complications",

abstract = "Left atrial appendage closure (LAAC) is noninferior to oral vitamin K antagonist therapy for the reduction of nonvalvular atrial fibrillation-related stroke risk. Currently, the procedure is most widely accepted in patients who cannot tolerate oral anticoagulants. This patient population is generally comorbid, making any reduction in procedural complications paramount. LAAC has important complications described in the periprocedural and postprocedural periods. The prevention and management of complications regarding vascular access, transseptal puncture, pericardial effusion, device embolization, stroke, air embolusperidevice leak, device-related thrombus and device erosion/ late pericardial effusion are discussed.",

keywords = "Complications, Left atrial appendage closure, Management, Prevention",

author = "Ben Wilkins and Motoki Fukutomi and {De Backer}, Ole and Lars S{\o}ndergaard",

year = "2020",

doi = "10.1016/j.ccep.2019.10.003",

language = "English",

volume = "12",

pages = "67--75",

journal = "Cardiac Electrophysiology Clinics",

issn = "1877-9182",

publisher = "W.B.Saunders Co.",

number = "1",

}

TY - JOUR

T1 - Left Atrial Appendage Closure

T2 - Prevention and Management of Periprocedural and Postprocedural Complications

AU - Wilkins, Ben

AU - Fukutomi, Motoki

AU - De Backer, Ole

AU - Søndergaard, Lars

PY - 2020

Y1 - 2020

N2 - Left atrial appendage closure (LAAC) is noninferior to oral vitamin K antagonist therapy for the reduction of nonvalvular atrial fibrillation-related stroke risk. Currently, the procedure is most widely accepted in patients who cannot tolerate oral anticoagulants. This patient population is generally comorbid, making any reduction in procedural complications paramount. LAAC has important complications described in the periprocedural and postprocedural periods. The prevention and management of complications regarding vascular access, transseptal puncture, pericardial effusion, device embolization, stroke, air embolusperidevice leak, device-related thrombus and device erosion/ late pericardial effusion are discussed.

AB - Left atrial appendage closure (LAAC) is noninferior to oral vitamin K antagonist therapy for the reduction of nonvalvular atrial fibrillation-related stroke risk. Currently, the procedure is most widely accepted in patients who cannot tolerate oral anticoagulants. This patient population is generally comorbid, making any reduction in procedural complications paramount. LAAC has important complications described in the periprocedural and postprocedural periods. The prevention and management of complications regarding vascular access, transseptal puncture, pericardial effusion, device embolization, stroke, air embolusperidevice leak, device-related thrombus and device erosion/ late pericardial effusion are discussed.

KW - Complications

KW - Left atrial appendage closure

KW - Management

KW - Prevention

U2 - 10.1016/j.ccep.2019.10.003

DO - 10.1016/j.ccep.2019.10.003

M3 - Review

C2 - 32067649

AN - SCOPUS:85076854031

VL - 12

SP - 67

EP - 75

JO - Cardiac Electrophysiology Clinics

JF - Cardiac Electrophysiology Clinics

SN - 1877-9182

IS - 1

ER -